MARS Atlas®, for Rapid CAR-T cell Therapy Manufacturing

The field of CAR-T therapy is evolving rapidly, with innovations making these treatments more accessible, efficient, and cost-effective. MARS Atlas represents a pivotal advancement, streamlining CAR-T manufacturing directly at the point of care and supporting new standards for potency, speed, and scalability. With cutting-edge technologies, the platform addresses key challenges in traditional production, driving progress toward the future where personalized cancer care is within reach for more patients.

· End-to-end workflow
With the three-step workflow and compatibility with peripheral blood, leukopaks, and PBMCs, MARS Atlas represents the future of an accessible, efficient, and flexible CAR-T therapy manufacturing platform.

· No expansion, high cell quality
Streamlined manufacturing process bypassing traditional T cell activation and expansion stages reduces T cell exhaustion and preserves cell stemness. The resulting CAR T cells more potent than conventional CAR-T treatments at four weeks post-infusion.

· Rapid and simple workflow
A three-step process, Isolation → Transduction → Purification, produces CAR-T cells within 24 to 48 hours. The rapid approach aims to minimize vein-to-vein time, especially important for critically ill patients and point-of-care settings.

· Cost-efficient and scalable
Designed to lower the cost of goods (COGs) through reducing labor, logistical demands, and equipment requirements. The compact, modular system supports small-scale, localized production for enabling widespread adoption and personalized cell therapy access.

Designed to transform the traditional CAR-T manufacturing paradigm by eliminating the need for long cell expansion, reducing costs, and accelerating the delivery of potent, patient-specific therapies.